The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for ...

Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...

China's homegrown medicines are expected to play a more important role in tumor treatment as domestic researchers and ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

Lung cancer is one of the most common, most dangerous, and most frequently talked about forms of cancer in the world. Of all ...

With tumor reduction seen in 48% of the 33 patients studied, the combination treatment had an overall response rate of 21% in ...

Liam Handley - who had suffered from anxiety for much of his life - went to his GP with chest pains, which his doctor put ...

The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...

The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR ...

Affimed (AFMD) stock plunged 23% after the company reported updated data from a clinical trial of AFM24/atezolizumab in the ...

Lawmaker says he expects a fight from insurance companies trying to end pre-authorizations. 'The system is kind of a mess for ...

A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer ...